Outlook Therapeutics Inc (OTLK) - News Archive

In a notable shift within its leadership, Outlook Therapeutics Inc. has appointed Faisal G. Sukhtian as Chairman of the Board of Directors as of January 31, 2025. Sukhtian steps into the role formerly held by Randy Thur...

Navigating the Waters of Innovation: Outlook Therapeutics Completes NORSE EIGHT Clinical Trial Results On January 16, 2025, Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company renowned for making stri...

Outlook Therapeutics, Inc. (Nasdaq: OTLK) is making waves in the biopharmaceutical waters with the announcement of preliminary topline results from the NORSE EIGHT clinical trial, aimed at tackling wet age-related macul...

Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss in older adults, making advancements in its treatment vitally important. Outlook Therapeutics, Inc. has garnered attention recently with t...

Outlook Therapeutics, a reputable biopharmaceutical company, has accomplished a significant milestone in the field of retina diseases. Recently, the United Kingdom (UK) Medicines and Healthcare products Regulatory Agenc...

Outlook Therapeutics Sets Path for Ophthalmic Treatment Breakthrough with Request for Marketing Authorization in the UKIselin, NJ-based biopharmaceutical company Outlook Therapeutics, Inc. (Nasdaq: OTLK) has set the bio...

Outlook Therapeutics Set to Present Groundbreaking Ophthalmic Formulation at 2024 Retina World Congress Outlook Therapeutics, Inc. (Nasdaq: OTLK), a prominent biopharmaceutical company specializing in the development an...

Outlook Therapeutics Secures $5.0 Million in Private Placement and Holds Potential for Additional $8 Million InvestmentOutlook Therapeutics, Inc. (Nasdaq: OTLK), a leading biopharmaceutical company dedicated to developi...

Outlook Therapeutics, a biopharmaceutical company dedicated to developing ophthalmic treatments for retinal diseases, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the...

Iselin-based biopharmaceutical company, Outlook Therapeutics, has successfully concluded its private placement, securing upfront gross proceeds of approximately $60 million. In addition, the company has the potential to...

Outlook Therapeutics, a renowned biopharmaceutical company, marked a significant milestone in its pursuit of FDA approval for the first ophthalmic formulation of bevacizumab in the treatment of retinal diseases. The com...

Outlook Therapeutics, a biopharmaceutical company, has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the NORSE EIGHT clinical trial protocol. This trial will evaluate ONS-5010, th...

Outlook Therapeutics Seeks FDA Approval for Ophthalmic Formulation of Bevacizumab with Non-Inferiority StudyISELIN, N.J., Dec. 19, 2023 - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company dedicated...